Avoiding locoregional overtreatment in older adults with early-stage breast cancer

Eliza H Lorentzen,Christina A Minami

DOI: https://doi.org/10.1016/j.clbc.2024.02.004

IF: 3.078

2024-02-15

Clinical Breast Cancer

Abstract:Advances in the treatment of older women with early-stage breast cancer, particularly opportunities for de-escalation of therapy, have afforded patients and providers opportunity to individualize care. As the majority of women ≥ 65 have estrogenreceptor positive, HER2-negative disease, locoregional therapy (surgery and/or radiation) may be tailored based on a patient's physiologic age to avoid either over or undertreatment. To determine who would drive benefit from more or less intensive therapy, an accurate assessment of an older patient's physiologic age and incorporation of patient-specific values are paramount. While there now exist wellvalidated geriatric assessment tools whose use is encouraged by the American Society of Clinical Oncology when considering systemic therapy, these instruments have not been widely integrated into the locoregional breast cancer care model. This review aims to highlight the importance of assessing frailty and the concepts of and over- and undertreatment, in the context of trial data supporting opportunities for safe deescalation of locoregional therapy, when treating older women with early-stage breast cancer.

oncology